uPAR expression increases in PBMNCs from G-CSF–treated donors. (A) Expression of uPAR on CD33⁺ and CD14⁺ cells during G-CSF–induced HSC mobilization in a representative case. Immunophenotyping of CD33⁺ and CD14⁺ uPAR–expressing cells was performed by 3-color flow cytometry on mononuclear and blast gates (R2 and R4, left), gating for side light scatter (SSC-H) and CD45⁺, with an anti-uPAR mAb and quantified as mean fluorescence intensity. (B) Percentages of CD33⁺ and CD14⁺ uPAR–expressing cells within blast and mononuclear gates in PBMNCs collected from 16 healthy donors before (day 0) or at various time points (days 3-5) of G-CSF administration. (C) Western blot analysis with an anti-uPAR polyclonal antibody of PBMNCs (50 μg total protein) collected from 6 representative donors before (day 0) or at different time points (days 3-5) of G-CSF administration.